Cytokinetics to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopa
Go back to Cytokinetics to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopa| CYTOKINETICS (NASDAQ: CYTK) | Delayed: 79.51 +0.34 (0.43%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $79.17 | 52 Week High | $13.18 | |||
| Open | $78.99 | 52 Week Low | $6.00 | |||
| Day High | $80.40 | P/E | N/A | |||
| Day Low | $78.27 | EPS | $-1.24 | |||
| Volume | 441,823 | |||||
